Treatment with Iron of Patients with Heart Failure With and Without Anemia

Heart Failure Clinics

Volumn 6, Issue 3, 2010, Pages 305-312

  Jelani, Qurat ul ain ^a   Attanasio, Philipp ^b   Katz, Stuart D ^a   Anker, Stefan D ^b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Anemia; Chronic heart failure; Intravenous iron; Iron deficiency

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIANEMIC AGENT; C REACTIVE PROTEIN; CARVEDILOL; FERRIC CARBOXYMALTOSE; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; IRON; METOPROLOL; PLACEBO; TRANSFERRIN; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANEMIA; CARDIAC PATIENT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG SAFETY; EXERCISE TOLERANCE; FERRITIN BLOOD LEVEL; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; INJECTION SITE DISCOLORATION; INJECTION SITE REACTION; IRON ABSORPTION; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON STORAGE; IRON THERAPY; IRON TRANSPORT; NONHUMAN; REVIEW; SYSTOLIC HEART FAILURE;

ANEMIA, IRON-DEFICIENCY; EXERCISE TOLERANCE; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; IRON; QUALITY OF LIFE;

EID: 77953567898     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2010.02.002     Document Type: Review

References (51)

1. Failla M.L. Trace elements and host defense: recent advances and continuing challenges. J Nutr 133 5 Suppl 1 (2003) 1443S-1447S
2. Gordeuk V.R., Bacon B.R., and Brittenham G.M. Iron overload: causes and consequences. Annu Rev Nutr 7 (1987) 485-508
3. Beard J.L. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 131 2S-2 (2001) 568S-579S [discussion: 80S]
4. Beutler E. Cell biology. "Pumping" iron: the proteins. Science 306 5704 (2004) 2051-2053
5. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102 3 (2003) 783-788
6. Swinkels D.W., Janssen M.C., Bergmans J., et al. Hereditary hemochromatosis: genetic complexity and new diagnostic approaches. Clin Chem 52 6 (2006) 950-968
7. Hider R.C. Nature of nontransferrin-bound iron. Eur J Clin Invest 32 Suppl 1 (2002) 50-54
8. Richardson D.R., and Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1331 1 (1997) 1-40
9. Meyron-Holtz E.G., Ghosh M.C., and Rouault T.A. Mammalian tissue oxygen levels modulate iron-regulatory protein activities in vivo. Science 306 5704 (2004) 2087-2090
10. Breuer W., Hershko C., and Cabantchik Z.I. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 23 3 (2000) 185-192
11. Pietrangelo A. Physiology of iron transport and the hemochromatosis gene. Am J Physiol Gastrointest Liver Physiol 282 3 (2002) G403-G414
12. Ponka P. Cellular iron metabolism. Kidney Int Suppl 69 (1999) S2-11
13. Andrews N.C. Disorders of iron metabolism. N Engl J Med 341 26 (1999) 1986-1995
14. Sullivan J.L. Is stored iron safe?. J Lab Clin Med 144 6 (2004) 280-284
15. Zheng H., Cable R., Spencer B., et al. Iron stores and vascular function in voluntary blood donors. Arterioscler Thromb Vasc Biol 25 8 (2005) 1577-1583
16. Ponikowski P., Chua T.P., Anker S.D., et al. Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation 104 5 (2001) 544-549
17. Leyva F., Anker S.D., Egerer K., et al. Hyperleptinaemia in chronic heart failure. Relationships with insulin. Eur Heart J 19 10 (1998) 1547-1551
18. von Haehling S., Jankowska E.A., and Anker S.D. Tumour necrosis factor-alpha and the failing heart-pathophysiology and therapeutic implications. Basic Res Cardiol 99 1 (2004) 18-28
19. Anker S.D., Volterrani M., Egerer K.R., et al. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. QJM 91 3 (1998) 199-203
20. Anker S.D., Volterrani M., Pflaum C.D., et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 38 2 (2001) 443-452
21. Doehner W., Rauchhaus M., Ponikowski P., et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46 6 (2005) 1019-1026
22. von Haehling S., Lainscak M., Springer J., et al. Cardiac cachexia: a systematic overview. Pharmacol Ther 121 3 (2009) 227-252
23. Komajda M., Anker S.D., Charlesworth A., et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 27 12 (2006) 1440-1446
24. Ezekowitz J.A., McAlister F.A., and Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107 2 (2003) 223-225
25. von Haehling S, Schefold JE, Mejc-Hodoscek L. Anemia in patients hospitalized for acute heart failure. Clin Res Cardiol, in press.
26. Silverberg D.S., Wexler D., and Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail 4 6 (2002) 681-686
27. Torre-Amione G., Bozkurt B., Deswal A., et al. An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol 14 3 (1999) 206-210
28. Sharma R., and Anker S.D. Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol 85 1 (2002) 161-171
29. Kalra P.R., Anagnostopoulos C., Bolger A.P., et al. The regulation and measurement of plasma volume in heart failure. J Am Coll Cardiol 39 12 (2002) 1901-1908
30. Anand I.S., Chandrashekhar Y., Ferrari R., et al. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 70 4 (1993) 357-362
31. Chatterjee B., Nydegger U.E., and Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. Eur J Heart Fail 2 4 (2000) 393-398
32. Ishani A., Weinhandl E., Zhao Z., et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 45 3 (2005) 391-399
33. Sharma R., Francis D.P., Pitt B., et al. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 25 12 (2004) 1021-1028
34. Mozaffarian D., Nye R., and Levy W.C. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 41 11 (2003) 1933-1939
35. Kalra P.R., Bolger A.P., Francis D.P., et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 91 7 (2003) 888-891
36. Witte K.K., Desilva R., Chattopadhyay S., et al. Are hematinic deficiencies the cause of anemia in chronic heart failure?. Am Heart J 147 5 (2004) 924-930
37. Westenbrink B.D., Voors A.A., and van Veldhuisen D.J. Is anemia in chronic heart failure caused by iron deficiency?. J Am Coll Cardiol 49 23 (2007) 2301-2302 [author reply: 2]
38. Berry C., Norrie J., Hogg K., et al. The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J 151 6 (2006) 1313-1321
39. Nanas J.N., Matsouka C., Karageorgopoulos D., et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48 12 (2006) 2485-2489
40. Weiss G., and Goodnough L.T. Anemia of chronic disease. N Engl J Med 352 10 (2005) 1011-1023
41. Ludwiczek S., Aigner E., Theurl I., et al. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 101 10 (2003) 4148-4154
42. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 5704 (2004) 2090-2093
43. Nemeth E., Rivera S., Gabayan V., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113 9 (2004) 1271-1276
44. Anker S.D., Comin Colet J., Filippatos G., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 25 (2009) 2436-2448
45. Katz S.D., and Zheng H. Peripheral limitations of maximal aerobic capacity in patients with chronic heart failure. J Nucl Cardiol 9 2 (2002) 215-225
46. Haas J.D., and Brownlie IV T. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 131 2S-2 (2001) 676S-688S [discussion: 88S-90S]
47. Davies K.J., Maguire J.J., Brooks G.A., et al. Muscle mitochondrial bioenergetics, oxygen supply, and work capacity during dietary iron deficiency and repletion. Am J Physiol 242 6 (1982) E418-427
48. Bolger A.P., Bartlett F.R., Penston H.S., et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48 6 (2006) 1225-1227
49. Toblli J.E., Lombrana A., Duarte P., et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50 17 (2007) 1657-1665
50. Okonko D.O., Grzeslo A., Witkowski T., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 51 2 (2008) 103-112
51. Usmanov R.I., Zueva E.B., Silverberg D.S., et al. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 21 2 (2008) 236-242